PMPeter F. A. Mulders

Peter F. A. Mulders

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter F. A. Mulders has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contrast-enhanced ultrasound with dispersion analysis for the localization of prostate cancer: correlation with radical prostatectomy specimens

    by Arnoud W. Postema, Maudy C. W. Gayet, Ruud J. G. van Sloun, Rogier R. Wildeboer, Christophe K. Mannaerts, C. Dilara Savci-Heijink, Stefan G. Schalk, Amir Kajtazovic, Henk van der Poel, Peter F. A. Mulders, et al.

    Purpose To determine the value of two-dimensional (2D) contrast-enhanced ultrasound (CEUS) imaging and the additional value of contrast ultrasound dispersion imaging (CUDI) for the localization of clinically significant prostate cancer (csPCa). Methods In this multicentre study, subjects scheduled for a radical prostatectomy underwent 2D CEUS imaging preoperatively. CUDI maps were generated from the CEUS recordings. Both CEUS recordings and CUDI maps were scored on the likelihood of presenting csPCa (any Gleason ≥ 4 + 3 and Gleason 3 + 4 larger than 0.5 mL) by five observers and compared to radical prostatectomy histopathology. An automated three-dimensional (3D) fusion protocol was used to match imaging with histopathology. Receiver operator curve (ROC) analysis was performed per observer and imaging modality. Results 133 of 216 (62%) patients were included in the final analysis. Average area under the ROC for all five readers for CEUS, CUDI and the combination was 0.78, 0.79 and 0.78, respectively. This yields a sensitivity and specificity of 81 and 64% for CEUS, 83 and 56% for CUDI and 83 and 55% for the combination. Interobserver agreement for CEUS, CUDI and the combination showed kappa values of 0.20, 0.18 and 0.18 respectively. Conclusion The sensitivity and specificity of 2D CEUS and CUDI for csPCa localization are moderate. Despite compressing CEUS in one image, CUDI showed a similar performance to 2D CEUS. With a sensitivity of 83% at cutoff point 3, it could become a useful imaging procedure, especially with 4D acquisition, improved quantification and combination with other US imaging techniques such as elastography.


  • Food intervention to make therapy with pazopanib more patient-friendly and affordable.

    by Floor Lubberman, Hans Gelderblom, Frank Jansman, Angela Colbers, Winette Ta van der Graaf, Peter Mulders, David M. Burger, Saskia Luelmo, Jan Den Hartigh, Carla M.L. Van Herpen, et al.

    11040 Background: Pazopanib has been registered for advanced soft tissue sarcoma (STS) and metastatic renal cell carcinoma (mRCC) and is used at a fixed oral dose of 800 mg taken fasted. However, ingesting pazopanib with food is a more patient friendly approach. Moreover, the occurrence of gastro-intestinal adverse events, a well-known side effect of pazopanib, could potentially be reduced when taken with food. Finally, a food intervention resulting in a better absorption and similar exposure to pazopanib, can lead to a reduced dose, which could significantly impact costs. The aim of the study was to establish the bio-equivalent dose of pazopanib taken with a continental breakfast compared to the standard intake of 800mg OD in fasted state. Methods: in this phase I cross-over multi-center study pazopanib pharmacokinetics (PK) were evaluated in STS and mRCC patients treated with 800 mg pazopanib in a fasted state, followed by 600 mg ingested with a continental breakfast based on PK evaluation. After both periods of 14 days, pazopanib plasma exposure was measured. Bioequivalence was assumed when the GMR (fed/fasted) of the AUC0-24h and Cmax and their 90% confidence interval (CI) were within the range of 0.8 and 1.25. Results: 19 patients were enrolled into the study, of whom 16 were eligible for PK analysis. GMR (fed/fasted) AUC0-24h was 1.09 (CI 1.02-1.17) and GMR Cmax was 1.12 (CI 1.04-1.20). 92% of our patients continued to use pazopanib with food. Conclusions: By a simple food intervention a 25% reduced dose of pazopanib results in an exposure, which is bioequivalent to 800 mg OD taken fasted. Most patients in this study choose to continue using pazopanib with food, emphasizing the patient friendliness of this approach for patients with STS and mRCC. Lastly, this approach may contribute to keep oncolytic therapy, such as pazopanib, more affordable and thus probably more available to all patients. Clinical trial information: NCT02138526.


    • 1 October 2015
      • Vol. 35  (10) , 5601-6

    Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.

    by Marye J Boers-Sonderen, Ingrid M E Desar, Jurgen J Fütterer, Sasja F Mulder, Lioe-Fee De Geus-Oei, Peter F Mulders, Winette T A Van Der Graaf, Wim J G Oyen, Carla M L Van Herpen

    To gain greater insight into the biological mechanisms occurring shortly after discontinuation of VEGFR TKIs treatment because of progressive disease (PD). Sixteen patients with PD during treatment with sorafenib or sunitinib were randomized to either directly stop the VEGFR TKI or to continue for another two weeks. At baseline (i.e. at the moment of PD) and after two weeks FDG-PET/CT, functional-MRI and blood biomarkers of disease were evaluated. A statistically significant difference in median change from baseline to two weeks later in K(trans) and LDH levels was observed between patients who directly stopped versus those who continued treatment (1.6 s(-1) versus -1.1s(-1), p=0.03; -73.0 U/L versus 52.0 U/L, p=0.008; respectively). There were no further differences between groups. Two weeks after discontinuation of VEGFR TKIs in mRCC because of PD, a rise in K(trans) accompanied by a decrease in LDH indicates an increase in tumor vascularization. This implies that at the moment of PD the effect of VEGFR TKIs is not completely exhausted.


  • Open Access

    Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy

    by Peter F. Mulders, Maria De Santis, Thomas Powles, Karim Fizazi

    Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of traditional short-term markers of treatment response observed with chemotherapy and contemporary hormonal treatments. Therefore, it is essential that clinicians understand the mechanism of action of sipuleucel-T and how this can translate in the clinic.


  • Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy

    by Peter F.A. Mulders, Arturo Molina, Michael Marberger, Fred Saad, Celestia S. Higano, Kim N. Chi, Jinhui Li, Thian Kheoh, Christopher M. Haqq, Karim Fizazi


  • Open Access

    Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma

    by Jeannette C. Oosterwijk-Wakka, Otto C. Boerman, Peter F. A. Mulders, Egbert Oosterwijk

    Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as diagnostic modality holds great promise for the future, both in detecting localized and advanced disease. Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase inhibitors, which constitutes the current standard treatment for mRCC, needs to be established.


  • Open Access

    Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

    by Gisele H. J. M. Leyten, Elisabeth A. Wierenga, J. P. Michiel Sedelaar, Inge M. Van Oort, Jurgen J. Futterer, Jelle O. Barentsz, Jack A. Schalken, Peter F. A. Mulders

    PCA3 (prostate cancer gene 3) and multiparametric 3 tesla MRI are new promising diagnostic tools in the detection of PCa. Our aim was to study the clinical value of the Progensa PCA3-test: its predictive value for biopsy outcome, Gleason score and MRI outcome. We evaluated, retrospectively, 591 patients who underwent a Progensa PCA3-test at the Radboud University Nijmegen Medical Centre between May 2006 and December 2009. Prostate biopsies were performed in 290 patients; a multiparametric 3 tesla MRI of the prostate was performed in 163/591 patients. The PCA3-score was correlated to biopsy results and MRI outcome. The results show that PCA3 was highly predictive for biopsy outcome (p < 0.001); there was no correlation with the Gleason score upon biopsy (p = 0.194). The PCA3-score of patients with a suspicious region for PCa on MRI was significantly higher (p < 0.001) than in patients with no suspicious region on MRI (52 vs. 21). In conclusion, PCA3 is a valuable diagnostic biomarker for PCa; it did not correlate with the Gleason score. Furthermore, multiparametric MRI outcome was significantly correlated with the PCA3-score. Thus, PCA3 could be used to select patients that require MRI. However, in patients with a negative PCA3 and high clinical suspicion of PCa, a multiparametric MRI should also be done.


  • Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).

    by Oscar B. Goodman, Thomas W. Flaig, Arturo Molina, Peter Mulders, Henrik Suttmann, Jinhui Li, Thian San Kheoh, Johann Sebastian De Bono, Howard I. Scher

    14 Background: VD is a negative prognostic factor in mCRPC patients (pts) and may be less responsive to hormonal therapy. AA, a selective androgen biosynthesis inhibitor, inhibits androgen synthesis from adrenal and intratumoral sources. Improved overall survival (OS) with AA vs prednisone (P) was demonstrated in a randomized trial of pts with mCRPC post-docetaxel (D). Here we further assess the effect of AA on OS and other clinical outcomes in post-D mCRPC pts with VD (liver or lung, but not nodal-only metastases). Methods: In COU-AA-301, pts with mCRPC previously treated with D were randomized 2:1 to AA (1000 mg) + P (5 mg BID) (n=797) or placebo + P (n=398). The primary end point was OS. Data shown herein represent the updated analysis (775 events) of patients with (n=352) or without (n=843) VD. Results: The OS benefit of AA was similarly improved in patients with VD (4.6 m) and without VD (4.8 m) (Table). Treatment with AA led to significant 40% and 32% reductions in the risk of radiographic progression or death in patients with VD or without VD, respectively. Soft-tissue objective response rates were superior with AA in both groups. PSA response rates (50% reduction) were significantly improved by AA in both groups. Grade 3/4 adverse events (AEs) were similar in both groups. Hypertension, hypokalemia, and LFT abnormalities were observed with AA in pts with and without VD. Conclusions: AA has substantial anti-tumor activity and provides clinical benefit including improvements in OS and rPFS in post-D mCRPC pts with VD indicating it is a therapeutically active treatment option for CRPC pts. Safety/tolerability of AA in pts with VD was similar to that reported previously in mCRPC. Clinical trial information: NCT00638690. [Table: see text]


    • 1 February 2013
      • Vol. 33  (2) , 553-7

    Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.

    by Maciej Salagierski, Peter Mulders, Jack A Schalken

    Prostate Cancer Gene-3 (PCA3) is highly prostate cancer (PCa)-specific and its application holds promise in identifying men with PCa. To determine whether the PCA3 score can be used relative to PCa clinical variables to predict biopsy outcome. PCA3 scores were assessed in a group of 80 patients using the Progensa assay (Gen-Probe, San Diego, CA, USA). The logistic regression algorithm was used to combine PCA3 results with the established biopsy risk factors including: age, prostate-specific antigen (PSA), digital rectal examination (DRE) and prostate volume (Pvol). In univariate analyses, the Progensa PCA3 score outperformed all biopsy risk predictors. A logistic regression algorithm using: age, PCA3, PSA, DRE and Pvol increased the area under the Receiver Operating Characteristic (ROC) curve from 0.72 for PCA3-alone to 0.85. Combining PCA3 results with PCa risk factors provides significant improvements over the use of PCA3- or PSA-alone in predicting the probability of a positive prostate biopsy.